• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lonny Reisman Discusses Big Data and Diabetes Care

Video

Diabetes care is incredibly complex and people are still trying to use data to predict issues with glycemic control, determine what the best combinations of drugs are, and to improve adherence with patients, explained Lonny Reisman, MD, CEO of HealthReveal and keynote speaker at Patient-Centered Diabetes Care.

Diabetes care is incredibly complex and people are still trying to use data to predict issues with glycemic control, determine what the best combinations of drugs are, and to improve adherence with patients, explained Lonny Reisman, MD, CEO of HealthReveal and keynote speaker at Patient-Centered Diabetes Care.

Transcript (slightly modified)

How does diabetes care benefit from the use of big data?

I think diabetes care is complex in many ways. There’s clearly an emphasis on glycemic control and, to the extent that there are risks to hypoglycemia, we’re learning, for example—there’s collaboration between Medtronic and IBM Watson—we’re learning how to predict hypoglycemia in patients at risk. There are certainly issues with poor glycemic control, severe hyperglycemia, and control of A1C.

So, again, understanding what combinations of drugs work, patient preferences, where the evidence is compelling regarding other benefits of certain drugs; Jardiance is an example where we’ve seen cardiovascular outcomes improved in well-conducted trials. So there’s just so much that we can do regarding what’s effective, learning what patients are willing to do or need to do in order to improve adherence and behavior.

Diabetes obviously is a critically important disease, with difficult and sometimes tragic complications, so I think we’re all highly motivated to do what we can to help that population.

Related Videos
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Leslie Fish, PharmD.
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Sarah Bajorek, PhD, BCACP, MBA.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.